Literature DB >> 18347287

Primary erythermalgia as a sodium channelopathy: screening for SCN9A mutations: exclusion of a causal role of SCN10A and SCN11A.

Joost P H Drenth1, Rene H M Te Morsche, Sahar Mansour, Peter S Mortimer.   

Abstract

OBJECTIVES: To elucidate the rate of missense mutations in the SCN9A gene (which encodes sodium channel Na(v)1.7) (OMIM 603415) among patients with primary erythermalgia and to examine the possibility that other sodium channels can cause the disease.
DESIGN: Case series.
SETTING: Department of Medicine, Radboud University Nijmegen, the Netherlands. PARTICIPANTS: Six patients with sporadic and 9 with unique familial primary erythermalgia. Interventions Questionnaire to determine clinical profile and sequencing of all coding exons from SCN9A and those of SCN10A (OMIM 604427) and SCN11A (OMIM 604385) in 2 selected cases with a clear family history of the disease. MAIN OUTCOME MEASURES: Detection of SCN9A mutation.
RESULTS: We identified 1 patient with an SCN9A mutation. This mutation (I848T) has been associated with primary erythermalgia. Sequencing of 2 other candidate genes did not show mutations in 2 patients with familial primary erythermalgia.
CONCLUSIONS: The Na(v)1.7 voltage-gated sodium channels are related to syndromes of altered nociception. We detected a low SCN9A mutation rate in patients with primary erythermalgia, suggesting that pain syndromes in the skin may have a polygenic basis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18347287     DOI: 10.1001/archderm.144.3.320

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  7 in total

1.  Dermatology in the postgenomic era: harnessing human variation for personalized medicine.

Authors:  Anthony E Oro
Journal:  Arch Dermatol       Date:  2008-03

Review 2.  Subtype-selective targeting of voltage-gated sodium channels.

Authors:  Steve England; Marcel J de Groot
Journal:  Br J Pharmacol       Date:  2009-10-20       Impact factor: 8.739

3.  Sodium channel Na v 1.7 immunoreactivity in painful human dental pulp and burning mouth syndrome.

Authors:  Kiran Beneng; Tara Renton; Zehra Yilmaz; Yiangos Yiangou; Praveen Anand
Journal:  BMC Neurosci       Date:  2010-06-08       Impact factor: 3.288

4.  Paroxysmal extreme pain disorder M1627K mutation in human Nav1.7 renders DRG neurons hyperexcitable.

Authors:  Sulayman D Dib-Hajj; Mark Estacion; Brian W Jarecki; Lynda Tyrrell; Tanya Z Fischer; Mark Lawden; Theodore R Cummins; Stephen G Waxman
Journal:  Mol Pain       Date:  2008-09-19       Impact factor: 3.395

5.  Regulation of Nav1.7: A Conserved SCN9A Natural Antisense Transcript Expressed in Dorsal Root Ganglia.

Authors:  Jennifer Koenig; Robert Werdehausen; John E Linley; Abdella M Habib; Jeffrey Vernon; Stephane Lolignier; Niels Eijkelkamp; Jing Zhao; Andrei L Okorokov; C Geoffrey Woods; John N Wood; James J Cox
Journal:  PLoS One       Date:  2015-06-02       Impact factor: 3.240

Review 6.  Erythromelalgia: a cutaneous manifestation of neuropathy?

Authors:  María Bibiana Leroux
Journal:  An Bras Dermatol       Date:  2018 Jan-Feb       Impact factor: 1.896

Review 7.  Genetic studies of human neuropathic pain conditions: a review.

Authors:  Katerina Zorina-Lichtenwalter; Marc Parisien; Luda Diatchenko
Journal:  Pain       Date:  2018-03       Impact factor: 7.926

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.